SeqLL, Inc. (SQL): Price and Financial Metrics


SeqLL, Inc. (SQL): $0.37

0.01 (+2.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SQL Stock Summary

  • SQL has a higher market value than just 2.13% of US stocks; more precisely, its current market capitalization is $5,471,233.
  • SEQLL INC's stock had its IPO on August 27, 2021, making it an older stock than only 2.97% of US equities in our set.
  • With a price/sales ratio of 69.56, SEQLL INC has a higher such ratio than 96.99% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SEQLL INC are VNDA, BJDX, PTE, AVAV, and NAVB.
  • To dig deeper into the stock's financial statements, go to SQL's page on browse-edgar?action=getcompany&CIK=0001605888.

SQL Valuation Summary

  • SQL's price/sales ratio is 69.6; this is 3563.16% higher than that of the median Healthcare stock.
  • SQL's price/earnings ratio has moved up 46.3 over the prior 19 months.

Below are key valuation metrics over time for SQL.

Stock Date P/S P/B P/E EV/EBIT
SQL 2023-03-17 69.6 1.3 -1.3 -1.5
SQL 2023-03-16 68.4 1.2 -1.3 -1.5
SQL 2023-03-15 40.4 0.8 -1.1 -0.7
SQL 2023-03-14 43.0 0.9 -1.2 -0.8
SQL 2023-03-13 43.9 0.9 -1.2 -0.8
SQL 2023-03-10 43.0 0.9 -1.2 -0.8

SQL Stock Price Chart Interactive Chart >

Price chart for SQL

SQL Price/Volume Stats

Current price $0.37 52-week high $2.40
Prev. close $0.36 52-week low $0.23
Day low $0.36 Volume 55,100
Day high $0.40 Avg. volume 3,550,041
50-day MA $0.61 Dividend yield N/A
200-day MA $0.68 Market Cap 5.13M

SeqLL, Inc. (SQL) Company Bio


SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It designs, develops, and manufactures genetic analysis technologies; and offers true single molecule sequencing (tSMS) platform that assists researchers to develop research, diagnostics, and therapeutics applications. The company also provides RNA sequencing services and instruments, which include Direct RNA Sequencing, a genetic testing and mapping service that captures polyadenylated RNA directly without conversion to cDNA; tSMS formalin fixed paraffin embedded (FFPE) service to analyze damaged or fragmented nucleic acids from formalin fixed paraffin embedded samples and other sources; micro RNA sequencing; and custom sequencing, and mapping and testing services, as well as gene expression studies, FFPE RNA Sequencing, biomarker discovery, fusion detection, rare mutation detection, transcriptome profiling, and cap analysis gene expression services. In addition, it offers DNA sequencing services and instruments, such as shotgun DNA sequencing, direct capture sequencing, cell free DNA sequencing, FFPE DNA sequencing, ancient DNA sequencing, and targeted sequencing, as well as microbiome studies, biomarker discovery, and tumor profiling services. Further, the company provides bioinformatics services comprising data processing, biomarkers research, pathway analysis, and gene expression analysis services, as well as undertakes various custom projects. It has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. The company serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. SeqLL Inc. was founded in 2013 and is based in Woburn, Massachusetts.


SQL Latest News Stream


Event/Time News Detail
Loading, please wait...

SQL Latest Social Stream


Loading social stream, please wait...

View Full SQL Social Stream

Latest SQL News From Around the Web

Below are the latest news stories about SEQLL INC that investors may wish to consider to help them evaluate SQL as an investment opportunity.

SeqLL Announces Fourth Quarter and Year End 2022 Financial Results

BILLERICA, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services, today announced its operating and financial results for the fourth quarter and year ended December 31, 2022. Year End 2022 Results and Financial Highlights Total revenues for the year ended December 31, 2022 were $0.079 million compared to $0.21 million during the year ended December 31, 2021, represen

Yahoo | March 17, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!

William White on InvestorPlace | February 24, 2023

Volatile SQL Stock Could Give Risk-Tolerant Investors a Wild Ride

SQL stock is a fast mover, and SeqLL is an intriguing life sciences technology company that recently secured a government contract.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | February 22, 2023

SeqLL Inc. Announces Closing of $1.8 Million Registered Direct Offering

BILLERICA, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (Nasdaq: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services, today announced the closing of its previously announced registered direct offering of 2,000,000 shares of common stock at a purchase price of $0.90 per share of common stock (the “Offering”). The gross proceeds to the Company from the registered direct offering were approximately $1.8 million before

Yahoo | February 15, 2023

SeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offering

BILLERICA, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a securities purchase agreement (the “Agreement”) with institutional investors to purchase 2,000,000 of its shares of common stock at a purchase price of $0.90 per share of common stock in a registered direct offering (the “Offering”). The gross proceeds to th

Yahoo | February 13, 2023

Read More 'SQL' Stories Here

SQL Price Returns

1-mo N/A
3-mo 37.14%
6-mo -51.32%
1-year -70.63%
3-year N/A
5-year N/A
YTD 27.28%
2022 -84.45%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6837 seconds.